Heterogeneous metallaphotoredox catalysis in a continuous-flow packed-bed reactor

• Wei-Hsin Hsu,
• Susanne Reischauer,
• Peter H. Seeberger,
• Bartholomäus Pieber and
• Dario Cambié

Beilstein J. Org. Chem. 2022, 18, 1123–1130, doi:10.3762/bjoc.18.115

• point for applications in large-scale synthesis or automated reaction optimization. Based on literature precedents on catalyst leaching in packed-bed reactors [37][38], we assumed that the decreased activity could be linked to nickel leaching. Based on ICP results on the reactor outlet collected in the

A comprehensive review of flow chemistry techniques tailored to the flavours and fragrances industries

• Guido Gambacorta,
• James S. Sharley and
• Ian R. Baxendale

Beilstein J. Org. Chem. 2021, 17, 1181–1312, doi:10.3762/bjoc.17.90

• brought about the product 127 in roughly 80% yield, however, effects of poisoning and catalyst leaching reduces the conversion by 20% over 8 hours of runtime. The poising was attributed to the presence of stationary areas caused by non-uniform flow in the reactor. Generally, this

One-pot multicomponent green Hantzsch synthesis of 1,2-dihydropyridine derivatives with antiproliferative activity

• Giovanna Bosica,
• Kaylie Demanuele,
• José M. Padrón and
• Adrián Puerta

Beilstein J. Org. Chem. 2020, 16, 2862–2869, doi:10.3762/bjoc.16.235

• , the reaction was left to carry on but stopped, and therefore catalyst leaching was not evident. Antiproliferative tests We selected the cancer cell lines A549 and SW1573 (nonsmall-cell lung), HBL-100, as well as T-47D (breast), HeLa (cervix), and WiDr (colon) to evaluate the antiproliferative activity

Ru complexes of Hoveyda–Grubbs type immobilized on lamellar zeolites: activity in olefin metathesis reactions

• Hynek Balcar,
• Naděžda Žilková,
• Martin Kubů,
• Michal Mazur,
• Zdeněk Bastl and
• Jiří Čejka

Beilstein J. Org. Chem. 2015, 11, 2087–2096, doi:10.3762/bjoc.11.225

• initial TOF for HGIIN+Cl−/SBA-15 and for HGIIN+Cl−/MCM-36 were close to each other; further progress of conversion curves indicated lower activity of HGIIN+Cl−/MCM-36 in comparison with HGIIN+Cl−/SBA-15. The selectivity to N-(2-trifluoroacetyl)-2,5-dihydropyrrole was 100%. Catalyst leaching and reusing

Efficient and selective chemical transformations under flow conditions: The combination of supported catalysts and supercritical fluids

• M. Isabel Burguete,
• Eduardo García-Verdugo and
• Santiago V. Luis

Beilstein J. Org. Chem. 2011, 7, 1347–1359, doi:10.3762/bjoc.7.159

• catalytic turnovers. A high catalytic efficiency was achieved with this system, reaching a TON value over 100,000 for the chiral transition metal complex, and a productivity of >150 kg product/g of Rh. The system operated with a space time yield (STY) of 0.3 kg·L−1 × h. Besides, the catalyst leaching was

Evaluation of a commercial packed bed flow hydrogenator for reaction screening, optimization, and synthesis

• Marian C. Bryan,
• David Wernick,
• Christopher D. Hein,
• James V. Petersen,
• John W. Eschelbach and
• Elizabeth M. Doherty

Beilstein J. Org. Chem. 2011, 7, 1141–1149, doi:10.3762/bjoc.7.132

• , over sequential runs, and with commercial catalyst cartridges. In addition, the consistency of the hydrogen flow was indirectly measured by in-line UV spectroscopy. Finally, system contamination due to catalyst leaching, and the resolution of this issue, is described. The impact of these factors on the

• run-to-run reproducibility of the H-Cube® reactor for screening and reaction optimization is discussed. Keywords: catalyst leaching; CatCart®; H-Cube®; packed bed flow hydrogenation; Introduction The potential advantages of heterogeneous catalytic flow hydrogenation over traditional batch reactor

Hoveyda–Grubbs type metathesis catalyst immobilized on mesoporous molecular sieves MCM-41 and SBA-15

• Hynek Balcar,
• Tushar Shinde,
• Naděžda Žilková and
• Zdeněk Bastl

Beilstein J. Org. Chem. 2011, 7, 22–28, doi:10.3762/bjoc.7.4

• nonpolar solvents (cyclohexane and hexane, respectively); (b) catalyst leaching in these solvents was extremely low, ensuring more than one order of magnitude lower Ru concentration in products compared to the upper limit permissible in pharmaceutical production (10 ppm [3]); and (c) similar catalyst